[The best of valvular heart disease in 2005].
The year 2005 has been rich in publications concerning valvular heart disease. In France, this year has been dominated by the publication of the French Society of Cardiologists' guidelines on the operative and interventional indications for acquired valvular heart disease: discussed and accepted formal indications based on the evidence in the literature. Non-ischaemic mitral insufficiency has been the subject of a major study that showed the high prognostic significance of echographic measuring of the area of the regurgitating orifice; patients with a surface > or =40 mm2 had a worse long-term prognosis and should undergo surgery early. The prognostic significance of BNP in valvular heart disease, such as mitral insufficiency and aortic stenosis, also became apparent. BNP is being used more and more for risk stratification for these conditions. The significance of anti-arrhythmic surgery combined with a mitral procedure has confirmed the harmful effect of atrial fibrillation, before and after the mitral surgery. The first randomised study into the use of statins to slow the progression of aortic stenosis was unfortunately disappointing, despite the various unrandomised studies that had opened a therapeutic pathway for this pathology, for which the prevalence is continually rising due to the ever increasing life expectancy. In mitral stenosis, a randomised study showed the long-term value of mitral commissurotomy in percutaneous mitral valvuloplasty, giving identical long-term results, in terms of mitral area, to those obtained with the classic Inoué balloon. In infectious endocarditis, surveys have confirmed the seriousness of this pathology as well as the slight advances in its prophylaxis. Other studies have confirmed the frequency and the severity of emboli, endocarditis due to Staphylococcus aureus, and the low risk of recurrence for endocarditis with the more and more accepted short course antibiotic treatment for patients undergoing surgery. Of course, this selection of publications is limited and by necessity subjective.
Hôpital cardiologique Louis Pradel, 28, avenue du Doyen Lépine, 69677 Bron. guy.de-gevigney@chu-lyon.fr
G
G
de Gevigney
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004452:Echocardiography; D004697:Endocarditis, Bacterial / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control; D006349:Heart Valve Diseases / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000628:therapy*; D006350:Heart Valve Prosthesis; D006801:Humans; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011643:Publishing / Q000639:trends; D012955:Societies, Medical
D000900:Anti-Bacterial Agents